Literature DB >> 6109265

Is the mesocortical dopaminergic system involved in Parkinson disease?

F Javoy-Agid, Y Agid.   

Abstract

Tyrosine hydroxylase was used to identify catecholaminergic neurons in the substantia nigra and ventral tegmental area of the human mesencephalon. High enzyme activity in the normal ventral tegmental area indicated the presence of numerous cathecholaminergic neurons, most likely dopamine cells. Tyrosine-hydroxylase activity was decreased in the ventral tegmental area of parkinsonian patients, implying a lesion of the mesocortical dopamine system in Parkinson disease.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6109265     DOI： 10.1212/wnl.30.12.1326

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  49 in total

1.  Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.

Authors:  Alessandro Tessitore; Ahmad R Hariri; Francesco Fera; William G Smith; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger; Venkata S Mattay
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent.

Authors:  L Krajcovicova; M Mikl; R Marecek; Irena Rektorova
Journal:  J Neural Transm (Vienna)       Date:  2011-10-15       Impact factor: 3.575

3.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

Review 4.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 5.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

6.  The late positive potential, emotion and apathy in Parkinson's disease.

Authors:  J Dietz; M M Bradley; J Jones; M S Okun; W M Perlstein; D Bowers
Journal:  Neuropsychologia       Date:  2013-01-12       Impact factor: 3.139

Review 7.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

8.  Repeated imipramine enhances sensitivity of the brain dopaminergic system related to exploratory behavior.

Authors:  A Smiałowski
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization.

Authors:  S J Wang; R S Liu; H C Liu; K N Lin; D E Shan; K K Liao; J L Fuh; L S Lee
Journal:  Eur J Nucl Med       Date:  1993-04

10.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.